Waters Corporation $WAT Shares Purchased by Glenview Trust Co

Glenview Trust Co raised its position in Waters Corporation (NYSE:WAT) by 37.5% during the first quarter, Holdings Channel.com reports. The firm owned 10,091 shares of the medical instruments supplier’s stock after buying an additional 2,754 shares during the period. Glenview Trust Co’s holdings in Waters were worth $3,005,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC increased its stake in shares of Waters by 543.8% during the 4th quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock valued at $14,146,000 after acquiring an additional 31,459 shares during the last quarter. Banque Cantonale Vaudoise grew its holdings in Waters by 329.0% in the fourth quarter. Banque Cantonale Vaudoise now owns 4,294 shares of the medical instruments supplier’s stock valued at $1,631,000 after purchasing an additional 3,293 shares during the period. Nordea Investment Management AB raised its stake in Waters by 15.8% during the fourth quarter. Nordea Investment Management AB now owns 13,550 shares of the medical instruments supplier’s stock worth $5,177,000 after purchasing an additional 1,848 shares during the period. Rockefeller Capital Management L.P. boosted its holdings in shares of Waters by 106.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,751 shares of the medical instruments supplier’s stock valued at $1,045,000 after purchasing an additional 1,420 shares during the last quarter. Finally, M&T Bank Corp grew its stake in shares of Waters by 1,662.4% during the 4th quarter. M&T Bank Corp now owns 64,273 shares of the medical instruments supplier’s stock valued at $24,413,000 after buying an additional 60,626 shares during the period. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Waters Trading Up 3.1%

WAT opened at $368.68 on Wednesday. The firm’s 50 day moving average is $362.62 and its 200-day moving average is $346.00. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $36.20 billion, a P/E ratio of 46.85, a P/E/G ratio of 2.16 and a beta of 1.20.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The firm’s revenue for the quarter was up 91.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Analysts expect that Waters Corporation will post 14.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on WAT. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $350.00 target price on shares of Waters in a report on Thursday, May 7th. UBS Group raised their price target on shares of Waters from $330.00 to $375.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Wolfe Research began coverage on shares of Waters in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $425.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a research note on Friday. Finally, Barclays upped their price target on shares of Waters from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $401.60.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.